Page 2 - Jersey Based Merck News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jersey based merck. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jersey Based Merck Today - Breaking & Trending Today

Merck Ends Development of Covid Drug It Acquired From OncoImmune

New Jersey-based Merck acquired the drug, MK-7110, through its $425 million acquisition of privately held biopharmaceutical company OncoImmune late last year.
An interim analysis of clinical trial data suggested the drug improved the chances of recovery for the sickest patients with Covid-19 and reduced the risk of death or respiratory failure.
However, Merck disclosed in February that U.S. regulators had asked for more data on the drug beyond the phase three trial already conducted. At the time, the company said it no longer expected to supply the U.S. with the drug in the first half of 2021.
Now, due to regulatory uncertainties and the time and resources needed to provide the additional data, Merck said it decided to discontinue the development of the drug and instead focus its efforts on advancing its other Covid-19 drug as well as accelerating production of the Johnson & Johnson vaccine. ....

Roy Baynes , Drug Administration , Jersey Based Merck , Ealth Amp Science , ராய் பேன்ஸ் , ஜெர்சி அடிப்படையிலானது மெர்க் , உயிரி தொழில்நுட்பவியல் ,

Covid 19 coronavirus: Why the three biggest vaccine makers failed on Covid-19

Covid 19 coronavirus: Why the three biggest vaccine makers failed on Covid-19
16 Feb, 2021 07:05 PM
9 minutes to read
GlaxoSmithKline, Merck and Sanofi are now left playing catch-up in the vaccine race. Photo / 123RF
Financial Times
GlaxoSmithKline, Merck and Sanofi are left playing catch-up to upstarts with new technology.
As pharmaceutical companies raced to develop Covid-19 vaccines, crossing the finishing line in record time, the world s three biggest vaccine makers were
also-rans.
GlaxoSmithKline, Merck and Sanofi are now left playing catch-up, after upstarts including Moderna and BioNTech demonstrated their mastery of new technologies that will shape the industry for years to come.
New Jersey-based Merck recently dropped its vaccine development programme completely, while Paris-based Sanofi and the UK s GSK are having to redo an early-stage trial of the jab they are jointly developing, after a dosing mistake. ....

United Kingdom , Zain Rizvi , Curevac Covid , Ron Renaud , Dan Mahony , Thomas Breuer , Hannah Kuchler , Leila Abboud , Mansoor Amiji , Laura Sutcliffe , Peter Hotez , Merck Gardasil , Soren Christiansen , Jo Walton , Ken Frazier , Credit Suisse , Sharps Technology , Baylor College , Baylor College Of Medicine , Jersey Based Merck , Paris Based Sanofi , Public Citizen , Translate Bio , Polar Capital , Co Vid , Corona Virus ,

Supreme Court Rejects Merck's Bid to Reinstate $2.5B Damage Award Against Rival

Supreme Court Rejects Merck’s Bid to Reinstate $2.5B Damage Award Against Rival
The U.S. Supreme Court on Tuesday rejected Merck & Co. Inc.’s bid to revive a $2.54 billion jury verdict it won against rival drugmaker Gilead Sciences Inc. for infringing a patent in a dispute over a blockbuster hepatitis C treatment.
The justices declined to take up Merck’s appeal of a lower court’s ruling that overturned the massive damages verdict after finding that Merck’s patent was invalid.
The case concerns a new generation of highly effective drugs for hepatitis C, a viral infection that can cause serious liver damage, able to cure more than 90% of patients, with few side effects. ....

New York , United States , Andrew Chung , Supreme Court , Merck Idenix Pharmaceuticals Inc , Us Court , Merck Co , Us Supreme Court On , Gilead Sciences Inc , Gilead Sciences , Jersey Based Merck , Idenix Pharmaceuticals , California Based Gilead , Federal Circuit , Will Dunham , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , ஆண்ட்ரூ சுங் , உச்ச நீதிமன்றம் , எங்களுக்கு நீதிமன்றம் , மெர்க் இணை , எங்களுக்கு உச்ச நீதிமன்றம் ஆன் , கிலியட் அறிவியல் இன்க் , கிலியட் அறிவியல் , ஜெர்சி அடிப்படையிலானது மெர்க் , கலிஃபோர்னியா அடிப்படையிலானது கிலியட் ,

U.S. Supreme Court rebuffs Merck appeal in hepatitis C patent fight with Gilead

2 Min Read
FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Linden, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid
(Reuters) - The U.S. Supreme Court on Tuesday rejected Merck & Co Inc’s bid to revive a $2.54 billion jury verdict it won against rival drugmaker Gilead Sciences Inc for infringing a patent in a dispute over a blockbuster hepatitis C treatment.
The justices declined to take up Merck’s appeal of a lower court’s ruling that overturned the massive damages verdict after finding that Merck’s patent was invalid.
The case concerns a new generation of highly effective drugs for hepatitis C, a viral infection that can cause serious liver damage, able to cure more than 90% of patients, with few side effects. ....

New York , United States , Andrew Chung , Thomson Reuters Trust Principles , Merck Idenix Pharmaceuticals Inc , Us Court , Us Supreme Court On , Gilead Sciences Inc , Supreme Court , Merck Co Inc , Jersey Based Merck , Idenix Pharmaceuticals Inc , California Based Gilead , Federal Circuit , Thomson Reuters Trust , Corporate Events , Bio Therapeutic Drugs Trbc Level 5 , Corporate Litigation , General News , Healthcare Trbc Level 1 , Intellectual Property , Judicial Process Court Cases Decisions , Biotechnology Amp Medical Research Trbc Level 4 , Major News , Pharmaceuticals Trbc Level 4 , Pharmaceuticals Trbc Level 3 ,